Compare SD & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SD | ALLO |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.7M | 539.4M |
| IPO Year | 2006 | 2018 |
| Metric | SD | ALLO |
|---|---|---|
| Price | $14.91 | $2.23 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | ★ $15.00 | $8.35 |
| AVG Volume (30 Days) | 272.8K | ★ 10.5M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | 12.43 | ★ 34.09 |
| EPS | ★ 0.50 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.65 | N/A |
| Revenue Next Year | $1.75 | $142,416.42 |
| P/E Ratio | $29.74 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.52 | $0.99 |
| 52 Week High | $18.45 | $4.46 |
| Indicator | SD | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.68 | 45.93 |
| Support Level | $13.66 | $2.12 |
| Resistance Level | $15.73 | $2.71 |
| Average True Range (ATR) | 0.44 | 0.13 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 33.99 | 43.55 |
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services. The company's primary areas of operation are the Mid-Continent in Oklahoma and Kansas.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.